Man Group plc Invests $1.71 Million in Smith & Nephew SNATS, Inc. $SNN

Man Group plc purchased a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 27,294 shares of the medical equipment provider’s stock, valued at approximately $1,712,000.

A number of other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Smith & Nephew SNATS during the 2nd quarter valued at about $505,323,000. River Road Asset Management LLC raised its holdings in Smith & Nephew SNATS by 13.8% in the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after buying an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Smith & Nephew SNATS by 5.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after buying an additional 100,697 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Smith & Nephew SNATS in the second quarter worth approximately $89,325,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Smith & Nephew SNATS by 44.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock valued at $33,436,000 after buying an additional 324,080 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. BTIG Research started coverage on shares of Smith & Nephew SNATS in a report on Monday. They issued a “neutral” rating for the company. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $28.98 on Wednesday. Smith & Nephew SNATS, Inc. has a fifty-two week low of $28.56 and a fifty-two week high of $38.79. The business’s 50-day moving average is $30.20 and its two-hundred day moving average is $31.57. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.

Smith & Nephew SNATS Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a dividend yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.